• 1
    Johansson SGO, Hourihane JO'B, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813824.
  • 2
    Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy 2000;64:1727.
  • 3
    Benavides J, Schoemaker H, Dana C, et al. In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Arzneimittelforschung 1995;45:551558.
  • 4
    Levrier J, Duval D, Prouteau M, et al. Anti-anaphylactic activity of the novel selective histamine H1-receptor antagonist mizolastine in the rodent. Arzneimittelforschung 1995;45:559568.
  • 5
    Yamada N. Effects of mizolastine on the infiltration of eosinophils. Jap Pharmacol Ther 1998;26:145150.
  • 6
    Sudo K, Nagai K, Yamada N. Inhibitory effect of mizolastine on 5-lipoxygenase. Jap Pharmacol Ther 1998;26:155157.
  • 7
    Yamada N, Funayama K. Inhibitory effects of mizolastine on the release of mediators and antagonistic effects against mediators. Jap Pharmacol Ther 1998;26:131138.
  • 8
    Funayama K, Honda K, Yamada N. Inhibitory effects of mizolastine on cytokine productions. Jap Pharmacol Ther 1998;26:139143.
  • 9
    Pichat P, Angel I, Arbilla S. Anti- inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneimittelforschung 1998;48:173178.
  • 10
    Kawabori S, Denburg JA, Schwartz LB, et al. Histochemical and immunohistochemical characteristics of mast cells in nasal polyps. Am J Respir Cell Mol Biol 1992;6:3743.
  • 11
    Stoop AE, Van Der H eijden HA, Biewenga J, Van Der B aan S. Eosinophils in nasal polyps and nasal mucosa: an immunohistochemical study. J Allergy Clin Immunol 1993;91:616622.
  • 12
    Xaubet A, Mullol J, Lopez E, et al. Comparison of the role of nasal polyp and normal nasal mucosal epithelial cells on in vitro eosinophil survival. Mediation by GM-CSF and inhibition by dexamethasone. Clin Exp Allergy 1994;24:307317.
  • 13
    Pinto S, Gallo O, Polli G, et al. Cyclooxygenase and lipoxygenase metabolite generation in nasal polyps. Prostagland Leukotr Ess Fatty Acids 1997;57:533537.
  • 14
    Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000;161:391398.
  • 15
    Rudack C, Bachert C, Stoll W. Effect of prednisolone on cytokine synthesis in nasal polyps. J Interferon Cytokine Res 1999;19:10311035.
  • 16
    Bachert C, Gevaert P, Holtappels G, Cuvelier C, Van C auvenberge P. Nasal polyposis: from cytokines to growth. Am J Rhinol 2000;14:279290.
  • 17
    Saji F, Nonaka M, Pawankar R. Expression of RANTES by IL-1 beta and TNF-alpha stimulated nasal polyps fibroblasts. Auris Nasus Larynx 2000;27:247252.
  • 18
    Drake-Lee AB. Histamine and its release from nasal polyps: preliminary communication. J R Soc Med 1984;77:120124.
  • 19
    Abe Y, Ogino S, Irifune M, et al. Histamine content, synthesis and degradation in human nasal mucosa. Clin Exp Allergy 1993;23:132136.
  • 20
    Finotto S, Dolovich J, Denburg JA, Jordana M, Marshall JS. Functional heterogeneity of mast cells isolated from different microenvironments within nasal polyp tissue. Clin Exp Immunol 1994;95:343350.
  • 21
    Crampette L, Mainprice B, Bloom M, Bousquet J, Campbell AM. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by terfenadine. Allergy 1996;51:346349.
  • 22
    Campbell A, Michel FB, Bremard-Oury C, Crampette L, Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs 1996;1:1519.
  • 23
    Lebel B, Crampette L, Vergnes C, Campbell AM, Bousquet J. Inhibition of mediator release from dispersed nasal polyp cells by cyclosporin A. Int Arch Allergy Immunol 1998;116:284287.
  • 24
    Campbell AM, Chanez P, Marty-Ané C, et al. Modulation of eicosanoid and histamine release from human dispersed lung cells by terfenadine. Allergy 1993;48:125129.
  • 25
    Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1992;31:1124.
  • 26
    Conover WJ. Some methods based on ranks. In ConoverWJ, editor. Practical Non-Parametric Statistics, 2nd edn. New York: J. Wiley and Sons, 1980.
  • 27
    Kaliner MA. The mediators of the early and late phases of allergic rhinitis. Adv Prostagland Thrombox Leukotr Res 1994;22:271278.
  • 28
    Howarth PH. The cellular basis for allergic rhinitis. Allergy 1995;50:610.
  • 29
    Naclerio RM. Pathophysiology of perennial allergic rhinitis. Allergy 1997;52:713.
  • 30
    Bachert C, Brostoff J, Scadding GK, et al. RIPERAN Study Group. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. Allergy 1998;53:969975.